# Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC

> **NCT06841874** · — · NO_LONGER_AVAILABLE · sponsor: **Nuvation Bio Inc.**

## Conditions studied

- Lung Neoplasms
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neoplasms by Site
- Neoplasms
- Lung Diseases
- Respiratory Tract Diseases
- Carcinoma
- Bronchogenic Carcinoma
- Non Small Cell Carcinoma of the Lung
- ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Taletrectinib

## Key facts

- **NCT ID:** NCT06841874
- **Lead sponsor:** Nuvation Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06841874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06841874, "Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06841874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*